Catumaxomab, which binds EpCAM on tumor cells and CD3 on T cells while retaining affinity to FcγR-positive cells, was the first clinically successful T-BsAb and was approved as a therapeutic agent for malignant ascites by the European Union in 2009 [141,142,143]. Here, EPCAM is linked to neoplasm.